Revolution Medicines, Inc.
RVMD
37 insider filings · Latest: Jun 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | Nov 25 9:28 PM | MARK A GOLDSMITH | Proposed Sale | 60,000 | $73.66 | $4.4M | — | View → |
| Nov 25, 2025 | Nov 25 9:25 PM | JACK LEE ANDERS | Proposed Sale | 5,418 | $73.66 | $399.1K | — | View → |
| Nov 18, 2025 | Nov 18 9:23 PM | MARK A GOLDSMITH | Proposed Sale | 20,000 | $69.14 | $1.4M | — | View → |
| Nov 18, 2025 | Nov 18 9:23 PM | JEFFREY TODD CISLINI | Proposed Sale | 13,388 | $69.14 | $925.6K | — | View → |
| Nov 12, 2025 | Nov 12 9:40 PM | MARK A GOLDSMITH | Proposed Sale | 20,000 | $64.08 | $1.3M | — | View → |
| Nov 11, 2025 | Nov 12 12:04 PM | JACK LEE ANDERS | Proposed Sale | 10,000 | $62.73 | $627.3K | — | View → |
| Nov 7, 2025 | Nov 7 9:38 PM | MARK A GOLDSMITH | Proposed Sale | 30,000 | $61.38 | $1.8M | — | View → |
| Oct 17, 2025 | Oct 17 8:18 PM | MARK A GOLDSMITH | Proposed Sale | 10,000 | $49.68 | $496.8K | — | View → |
| Oct 17, 2025 | Oct 17 8:17 PM | JEFFREY TODD CISLINI | Proposed Sale | 12,000 | $49.68 | $596.2K | — | View → |
| Oct 16, 2025 | Oct 16 8:21 PM | MARK A GOLDSMITH | Proposed Sale | 10,000 | $49.56 | $495.6K | — | View → |
| Sep 24, 2025 | Sep 24 8:21 PM | JEFFREY TODD CISLINI | Proposed Sale | 1,799 | $44.21 | $79.5K | — | View → |
| Sep 15, 2025 | Sep 16 1:32 AM | Wei Lin | Proposed Sale | 2,131 | $46.55 | $99.2K | — | View → |
| Sep 15, 2025 | Sep 16 1:28 AM | Kelsey Stephen Michael | Proposed Sale | 5,296 | $46.55 | $246.5K | — | View → |
| Sep 15, 2025 | Sep 16 1:24 AM | Horn Margaret A | Proposed Sale | 4,712 | $46.55 | $219.3K | — | View → |
| Sep 15, 2025 | Sep 16 1:20 AM | GOLDSMITH MARK A | Proposed Sale | 13,236 | $46.55 | $616.1K | — | View → |
| Sep 15, 2025 | Sep 16 1:18 AM | Cislini Jeff | Proposed Sale | 1,842 | $46.55 | $85.7K | — | View → |
| Sep 15, 2025 | Sep 16 1:14 AM | Anders Jack | Proposed Sale | 2,128 | $46.55 | $99.1K | — | View → |
| Sep 11, 2025 | Sep 11 8:30 PM | STEPHEN M. KELSEY | Proposed Sale | 150,000 | $40.45 | $6.1M | — | View → |
| Sep 2, 2025 | Sep 2 8:41 PM | JACK LEE ANDERS | Proposed Sale | 10,000 | $37.97 | $379.7K | — | View → |
| Jun 20, 2025 | Jun 20 8:23 PM | JEFFREY TODD CISLINI | Proposed Sale | 1,912 | $39.93 | $76.3K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 1 10:25 PM | Sushil PatelDirector | Option Exercise | 2,955 | $37.54 | 13,000(D) | View → |
| Jun 24, 2026 | Jun 26 8:10 PM | Jack AndersChief Financial Officer | Option Exercise | 20,000 | $18.56 | 20,600(D) | View → |
| Jun 18, 2026 | Jun 23 9:57 PM | Lorence H. KimDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:52 PM | Alexis BorisyDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Elizabeth M AndersonDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Sandra HorningDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:44 PM | Frank ClyburnDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:43 PM | Sushil PatelDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:42 PM | Flavia BorelliniDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 17, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 29,600 | $40.74 | 114,275(D) | View → |
| Jun 15, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 60,400 | $40.74 | 75,052(D) | View → |
| Jun 11, 2026 | Jun 15 8:05 PM | Margaret A HornChief Operating Officer | Option Exercise | 10,000 | $42.45 | 91,194(D) | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,121 | $33.62 | 106,109(D) | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
Page 1 of 2
Next →